CRLF3

Across TCGA pan-cancer cohorts, CRLF3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRLF3 data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CRLF3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CRLF3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where CRLF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.965	0.892	.008	6	view →
HNSC	OS	Median	All	0.790	0.609	.024	5	view →
UCEC	OS	Median	II,III,IV	1.000	0.647	.017	4	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CRLF3–LUAD (DFS)

Open the LUAD breakdown →